BUZZ-Ionis falls after AstraZeneca-partnered drug fails late-stage heart disease trial

AstraZeneca PLC AZN	0.00	0.00%
Alnylam Pharmaceuticals, Inc ALNY	0.00	0.00%
Ionis Pharmaceuticals, Inc. IONS	0.00	0.00%
BridgeBio Pharma BBIO	0.00	0.00%

** Ionis Pharmaceuticals IONS.O slides 21.8% premarket to $67.80

** Co's nerve disease drug Wainua, made in partnership with AstraZeneca AZN.L fails to meet main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial

** Setback dents what analysts predicted could be a $2 billion peak-sales opportunity for the drug

** Shares of Alnylam Pharmaceuticals ALNY.O and BridgeBio Pharma BBIO.O which have approved drugs for the disease, are up 15.3% and 9.9% respectively

** As of last close, IONS up 6.7% YTD

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.